Reported Earnings • Jun 01
Full year 2026 earnings released: EPS: ₹1.71 (vs ₹0.34 in FY 2025) Full year 2026 results: EPS: ₹1.71 (up from ₹0.34 in FY 2025). Revenue: ₹314.8m (down 6.3% from FY 2025). Net income: ₹27.9m (up 400% from FY 2025). Profit margin: 8.9% (up from 1.7% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹37.09, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total loss to shareholders of 18% over the past three years. Announcement • May 21
Biofil Chemicals and Pharmaceuticals Limited to Report Q4, 2026 Results on May 30, 2026 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026 Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹32.39, the stock trades at a trailing P/E ratio of 19x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 27% over the past three years. Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: ₹0.05 (vs ₹0.10 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.05 (down from ₹0.10 in 3Q 2025). Revenue: ₹9.35m (down 93% from 3Q 2025). Net income: ₹792.0k (down 52% from 3Q 2025). Profit margin: 8.5% (up from 1.2% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Feb 03
Biofil Chemicals and Pharmaceuticals Limited to Report Q3, 2026 Results on Feb 13, 2026 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q3, 2026 results on Feb 13, 2026 New Risk • Feb 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (33% accrual ratio). Market cap is less than US$10m (₹563.4m market cap, or US$6.14m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (₹455m revenue, or US$5.0m). Reported Earnings • Nov 15
Second quarter 2026 earnings released: EPS: ₹0.05 (vs ₹0.015 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.05 (up from ₹0.015 in 2Q 2025). Revenue: ₹136.0m (up 460% from 2Q 2025). Net income: ₹836.0k (up 243% from 2Q 2025). Profit margin: 0.6% (down from 1.0% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • Nov 07
Biofil Chemicals and Pharmaceuticals Limited to Report Q2, 2026 Results on Nov 13, 2025 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q2, 2026 results on Nov 13, 2025 Announcement • Aug 13
Biofil Chemicals and Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2025 Biofil Chemicals and Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2025, at 15:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2026 earnings released: EPS: ₹1.48 (vs ₹0.10 in 1Q 2025) First quarter 2026 results: EPS: ₹1.48 (up from ₹0.10 in 1Q 2025). Revenue: ₹92.6m (up 9.3% from 1Q 2025). Net income: ₹24.1m (up ₹22.4m from 1Q 2025). Profit margin: 26% (up from 2.0% in 1Q 2025). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Aug 12
Biofil Chemicals and Pharmaceuticals Limited Appoints Finance Committee of Board of Directors, Effective from 12th August, 2025 Biofil Chemicals and Pharmaceuticals Limited board at its meeting held on August 12, 2025 announced Constitution of Finance Committee of Board of Directors; effective from 12th August, 2025 in the Following Manner: Mr. Ketan Shah- Whole Time Director as Chairperson; Mr. Meet Shah- Non-Executive Non- Independent Director as member. Announcement • Aug 04
Biofil Chemicals and Pharmaceuticals Limited to Report Q1, 2026 Results on Aug 12, 2025 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q1, 2026 results on Aug 12, 2025 New Risk • Jun 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Market cap is less than US$10m (₹781.3m market cap, or US$9.03m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹334m revenue, or US$3.9m). Reported Earnings • Jun 02
Full year 2025 earnings released: EPS: ₹0.34 (vs ₹0.44 in FY 2024) Full year 2025 results: EPS: ₹0.34 (down from ₹0.44 in FY 2024). Revenue: ₹337.1m (down 17% from FY 2024). Net income: ₹5.58m (down 21% from FY 2024). Profit margin: 1.7% (in line with FY 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 4% per year. Announcement • May 22
Biofil Chemicals and Pharmaceuticals Limited to Report Q4, 2025 Results on May 30, 2025 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q4, 2025 results on May 30, 2025 Announcement • Mar 22
Biofil Chemicals and Pharmaceuticals Limited Confirms Appointment of Meet Shah as Non-Executive Non-Independent Director Biofil Chemicals and Pharmaceuticals Limited announced the confirmation of Mr. Meet Shah's appointment as a Director under the category of Promoter Non-Executive Non-Independent Director. Mr. Meet Shah was initially appointed as an Additional Director effective from December 30, 2024. His appointment was confirmed by the members through a postal ballot conducted via remote e-voting mechanism, which was deemed to have been passed on March 21, 2025. Mr. Meet Shah, aged 32, holds a Bachelor of Business Administration (BBA) degree and has 11 years of experience in sales and marketing at Biofil Chemicals & Pharmaceuticals Ltd. Date of Birth is April 4, 1992. Announcement • Mar 12
Biofil Chemicals and Pharmaceuticals Limited Announces Demise of Ramesh Shah, Managing Director Biofil Chemicals and Pharmaceuticals Limited announced demise of Mr. Ramesh Shah, Managing Director on March 10, 2025. Mr. Ramesh Shah was associated with Company since from incorporation and he was founder member of the Company and the Company immensely benefitted from his vision and contribution during his tenure. Announcement • Mar 11
Biofil Chemicals and Pharmaceuticals Limited Announces Demise of Ramesh Shah, Chairman Biofil Chemicals and Pharmaceuticals Limited announced demise of Mr. Ramesh Shah, Chairman on March 10, 2025. Mr. Ramesh Shah was associated with Company since from incorporation and he was founder member of the Company and the Company immensely benefitted from his vision and contribution during his tenure. Reported Earnings • Feb 12
Third quarter 2025 earnings released: EPS: ₹0.10 (vs ₹0.06 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.10 (up from ₹0.06 in 3Q 2024). Revenue: ₹142.2m (up 183% from 3Q 2024). Net income: ₹1.65m (up 76% from 3Q 2024). Profit margin: 1.2% (down from 1.9% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Feb 04
Biofil Chemicals and Pharmaceuticals Limited to Report Q3, 2025 Results on Feb 11, 2025 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q3, 2025 results on Feb 11, 2025 New Risk • Jan 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹830.6m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (₹830.6m market cap, or US$9.63m). Minor Risk Revenue is less than US$5m (₹315m revenue, or US$3.6m). Announcement • Dec 19
Biofil Chemicals and Pharmaceuticals Limited Announces Resignation Anisha Mangal as Company Secretary and Compliance Officer Biofil Chemicals and Pharmaceuticals Limited announced that Ms. Anisha Mangal has tendered her resignation vide her resignation letter dated 16th December, 2024 from the post of Company Secretary and Compliance Officer of the Company with effect from the close of business hours on 16th December, 2024. Announcement • Nov 27
Biofil Chemicals and Pharmaceuticals Limited Announces Resignation of Romil Shah as Non Executive Non Independent Director Biofil Chemicals and Pharmaceuticals Limited informed that Mr. Romil Shah (DIN: 00326110) has tendered his resignation from the post of Non Executive Non Independent Director of the Company with effect from the close of business hours on 27th November, 2024. The resignation letter shall be placed before the Board of Directors in the upcoming Board Meeting for its consideration and formal acceptance in accordance with the aforementioned regulation. Reported Earnings • Nov 18
Second quarter 2025 earnings released: EPS: ₹0.01 (vs ₹0.08 in 2Q 2024) Second quarter 2025 results: EPS: ₹0.01 (down from ₹0.08 in 2Q 2024). Revenue: ₹24.3m (down 86% from 2Q 2024). Net income: ₹244.0k (down 80% from 2Q 2024). Profit margin: 1.0% (up from 0.7% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Nov 08
Biofil Chemicals and Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 14, 2024 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q2, 2025 results on Nov 14, 2024 New Risk • Sep 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Profit margins are more than 30% lower than last year (1.4% net profit margin). Market cap is less than US$100m (₹1.44b market cap, or US$17.2m). Announcement • Sep 14
Biofil Chemicals and Pharmaceuticals Limited Announces Appointment of Ms. Anisha Mangal as Company Secretary (Kmp) Biofil Chemicals and Pharmaceuticals Limited announced appointment of Ms. Anisha Mangal as company secretary. A) Date of appointment. 14th September, 2024. Brief profile: Date of Birth 9th September, 1996. Fathers Name Mr. Chetan Mangal. Education Qualification: Company Secretary. Ms. Anisha Mangal is an Associate Member of the Institute of Company Secretaries of India (ICSI) having membership No. A70128, besides holding the Membership of the ICSI. Reported Earnings • Aug 15
First quarter 2025 earnings released: EPS: ₹0.10 (vs ₹0.15 in 1Q 2024) First quarter 2025 results: EPS: ₹0.10 (down from ₹0.15 in 1Q 2024). Revenue: ₹84.7m (up 248% from 1Q 2024). Net income: ₹1.69m (down 31% from 1Q 2024). Profit margin: 2.0% (down from 10.0% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year. Announcement • Aug 14
Biofil Chemicals and Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024 Biofil Chemicals and Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time. Announcement • Aug 08
Biofil Chemicals and Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 13, 2024 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Announcement • Jul 04
Biofil Chemicals and Pharmaceuticals Limited Announces Resignation of Shweta Verma as Company Secretary and Compliance Officer Biofil Chemicals and Pharmaceuticals Limited announced that Ms. Shweta Verma has tendered her resignation from the post of Company Secretary and Compliance Officer of the Company with effect from the close of business hours on 3rd July, 2024. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹0.44 (vs ₹0.34 in FY 2023) Full year 2024 results: EPS: ₹0.44 (up from ₹0.34 in FY 2023). Revenue: ₹405.3m (up 35% from FY 2023). Net income: ₹7.09m (up 27% from FY 2023). Profit margin: 1.8% (down from 1.9% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • May 24
Biofil Chemicals and Pharmaceuticals Limited to Report Q4, 2024 Results on May 30, 2024 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q4, 2024 results on May 30, 2024 Announcement • Mar 30
Biofil Chemicals and Pharmaceuticals Limited Announces Smt. Shaila Jain Will Retire from Independent Directorship as Well as from All the Committees of Board of Directors, Effective 31 March, 2024 Biofil Chemicals and Pharmaceuticals Limited informed that Smt. Shaila Jain will complete her second and final term as an Independent Director pursuant to the provisions of Sub-Section 11 of Section 149 of the Companies Act, 2013 with effect from the close of business hours on 31st March, 2024 consequently she will retire from Independent Directorship as well as from all the Committees of Board of Directors of the Company. Reported Earnings • Feb 09
Third quarter 2024 earnings released: EPS: ₹0.06 (vs ₹0.06 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.06 (in line with 3Q 2023). Revenue: ₹50.3m (up 237% from 3Q 2023). Net income: ₹933.0k (down 6.8% from 3Q 2023). Profit margin: 1.9% (down from 6.7% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • Jan 31
Biofil Chemicals and Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q3, 2024 results on Feb 06, 2024 New Risk • Jan 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Profit margins are more than 30% lower than last year (1.9% net profit margin). Revenue is less than US$5m (₹349m revenue, or US$4.2m). Market cap is less than US$100m (₹1.08b market cap, or US$13.0m). Reported Earnings • Nov 12
Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.03 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.08 (up from ₹0.03 in 2Q 2023). Revenue: ₹174.0m (up ₹147.8m from 2Q 2023). Net income: ₹1.23m (up 170% from 2Q 2023). Profit margin: 0.7% (down from 1.7% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Announcement • Nov 02
Biofil Chemicals and Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 09, 2023 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q2, 2024 results on Nov 09, 2023 Announcement • Sep 28
Biofil Chemicals and Pharmaceuticals Limited Announces Change in Designation of Gayatri Padiyar from Additional Director to Non-Executive Independent Director Biofil Chemicals and Pharmaceuticals Limited announced that at its AGM held on September 27, 2023, approved the change in designation of Smt. Gayatri Padiyar from Additional Director to Non-Executive Independent Director. Date of change: 27th September, 2023. Term of appointment: 5 years, that is 14th August, 2023 to 13th August, 2028. Age: 46 years. Education/Qualification: Graduate. Smt. Gayatri Padiyar is a proprietor in Anjali Marketing Services holding 8 years' experience in marketing and customer relation. Announcement • Aug 25
Biofil Chemicals and Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2023 Biofil Chemicals and Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2023, at 15:00 Indian Standard Time. New Risk • Aug 17
New major risk - Revenue and earnings growth Earnings have declined by 3.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.5% per year over the past 5 years. Market cap is less than US$10m (₹743.5m market cap, or US$8.94m). Minor Risk Revenue is less than US$5m (₹202m revenue, or US$2.4m). Reported Earnings • Aug 16
First quarter 2024 earnings released: EPS: ₹0.15 (vs ₹0.13 in 1Q 2023) First quarter 2024 results: EPS: ₹0.15 (up from ₹0.13 in 1Q 2023). Revenue: ₹24.6m (down 80% from 1Q 2023). Net income: ₹2.44m (up 18% from 1Q 2023). Profit margin: 9.9% (up from 1.7% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Announcement • Aug 06
Biofil Chemicals and Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 14, 2023 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Reported Earnings • Jun 04
Full year 2023 earnings released: EPS: ₹0.29 (vs ₹0.43 in FY 2022) Full year 2023 results: EPS: ₹0.29 (down from ₹0.43 in FY 2022). Revenue: ₹301.3m (up 35% from FY 2022). Net income: ₹5.60m (down 20% from FY 2022). Profit margin: 1.9% (down from 3.1% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 48% per year, which means it is well ahead of earnings. Announcement • May 23
Biofil Chemicals and Pharmaceuticals Limited to Report Q4, 2023 Results on May 30, 2023 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q4, 2023 results on May 30, 2023 Reported Earnings • Feb 16
Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.21 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.06 (down from ₹0.21 in 3Q 2022). Revenue: ₹14.9m (down 12% from 3Q 2022). Net income: ₹1.00m (down 71% from 3Q 2022). Profit margin: 6.7% (down from 20% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 63% per year, which means it is well ahead of earnings. Announcement • Feb 08
Biofil Chemicals and Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 14, 2023 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q3, 2023 results on Feb 14, 2023 Announcement • Dec 24
Biofil Chemicals and Pharmaceuticals Limited Announces Changes in Company Secretary / Compliance Officer Biofil Chemicals and Pharmaceuticals Limited announced Resignation of SHIKHA KHILWANI from CS (KMP) & Compliance Officer due to pre- occupation and other personal reasons. Date of Cessation:- 23rd December, 2022. Appointment of SHWETA VERMA as Company Secretary (KMP) and Compliance officer of the Company. Announcement • Dec 17
Biofil Chemicals and Pharmaceuticals Limited Announces Resignation of Shikha Khilwani as Company Secretary and Compliance Officer, Effective 23 December, 2022 Biofil Chemicals and Pharmaceuticals Limited announced Resignation of Ms. Shikha Khilwani from the post of Company Secretary (KMP) and Compliance officer of the Company. Reason for Change is due to pre-occupation and other personal reasons. Date of Cessation: letter from Company secretary received for resignation with effect from 23 December, 2022. Reported Earnings • Nov 20
Second quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.13 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.03 (down from ₹0.13 in 2Q 2022). Revenue: ₹26.4m (down 81% from 2Q 2022). Net income: ₹455.0k (down 79% from 2Q 2022). Profit margin: 1.7% (up from 1.5% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 127% per year, which means it is well ahead of earnings. Announcement • Nov 16
Biofil Chemicals and Pharmaceuticals Limited Appoints Pawan Singh Rajput as Chief Financial Officer Biofil Chemicals and Pharmaceuticals Limited announced the appointment of Chief Financial Officer as well as Key Managerial Personnel of the company. Date of Appointment is November 14, 2022. Mr. Pawan Singh Rajput aged 32 years is Finance and accounting professional having about 5 years experience in running the accounting and financial activities of an organization. And expert in reports on costs, productivity, margins and company expenditures. Reported Earnings • Aug 11
First quarter 2023 earnings released: EPS: ₹0.13 (vs ₹0.11 in 1Q 2022) First quarter 2023 results: EPS: ₹0.13 (up from ₹0.11 in 1Q 2022). Revenue: ₹123.2m (up 129% from 1Q 2022). Net income: ₹2.06m (up 19% from 1Q 2022). Profit margin: 1.7% (down from 3.2% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 95% per year, which means it is well ahead of earnings. Announcement • Jun 23
Biofil Chemicals and Pharmaceuticals Limited Announces Resignation of Jitendra Kumar Sahu as CFO , Effective on June 30, 2022 Biofil Chemicals and Pharmaceuticals Limited announced the resignation of Mr. Jitendra Kumar Sahu from the post of Chief Financial officer. The date of cessation is 30 June 2022. Reason for change:- Due to propose shifting at other location to avail good opportunity. Reported Earnings • Jun 04
Full year 2022 earnings released: EPS: ₹0.44 (vs ₹0.76 in FY 2021) Full year 2022 results: EPS: ₹0.44 (down from ₹0.76 in FY 2021). Revenue: ₹225.3m (down 38% from FY 2021). Net income: ₹6.98m (down 44% from FY 2021). Profit margin: 3.1% (down from 3.4% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 90% per year, which means it is well ahead of earnings. Announcement • May 22
Biofil Chemicals and Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q4, 2022 results on May 30, 2022 Reported Earnings • Feb 17
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.21 (down from ₹0.31 in 3Q 2021). Revenue: ₹17.0m (down 47% from 3Q 2021). Net income: ₹3.40m (down 34% from 3Q 2021). Profit margin: 20% (up from 16% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 125% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 03
Full year 2021 earnings released: EPS ₹0.76 (vs ₹0.74 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹365.5m (up 23% from FY 2020). Net income: ₹12.4m (up 2.8% from FY 2020). Profit margin: 3.4% (down from 4.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has increased by 77% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improved over the past week After last week's 17% share price gain to ₹74.15, the stock trades at a trailing P/E ratio of 66.7x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 388% over the past three years. Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹72.65, the stock trades at a trailing P/E ratio of 65.3x, down from the previous P/E ratio of 77.3x. Average P/E is 19x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 376%. Valuation Update With 7 Day Price Move • Feb 26
Investor sentiment improved over the past week After last week's 27% share price gain to ₹84.75, the stock is trading at a trailing P/E ratio of 76.2x, up from the previous P/E ratio of 59.9x. This compares to an average P/E of 20x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 443%. Reported Earnings • Feb 17
Third quarter 2021 earnings released: EPS ₹0.31 (vs ₹0.14 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₹32.1m (down 75% from 3Q 2020). Net income: ₹5.13m (up 123% from 3Q 2020). Profit margin: 16% (up from 1.8% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorated over the past week After last week's 21% share price decline to ₹72.40, the stock is trading at a trailing P/E ratio of 77.6x, down from the previous P/E ratio of 98.7x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 334%. Announcement • Feb 06
Biofil Chemicals and Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 12, 2021 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q3, 2021 results on Feb 12, 2021 Is New 90 Day High Low • Feb 01
New 90-day low: ₹97.15 The company is down 3.0% from its price of ₹99.75 on 03 November 2020. The Indian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Is New 90 Day High Low • Nov 13
New 90-day high: ₹133 The company is up 361% from its price of ₹28.90 on 14 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Announcement • Nov 05
Biofil Chemicals and Pharmaceuticals Limited to Report Q2, 2021 Results on Nov 11, 2020 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q2, 2021 results on Nov 11, 2020 Is New 90 Day High Low • Oct 22
New 90-day high: ₹90.40 The company is up 337% from its price of ₹20.70 on 24 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period. Is New 90 Day High Low • Oct 05
New 90-day high: ₹58.70 The company is up 346% from its price of ₹13.16 on 07 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 18% over the same period. Announcement • Aug 21
Biofil Chemicals and Pharmaceuticals Limited to Report Q1, 2021 Results on Aug 25, 2020 Biofil Chemicals and Pharmaceuticals Limited announced that they will report Q1, 2021 results on Aug 25, 2020